Director at $MDB sells 5,602 shares in insider sale.

On September 19, 2025, DWIGHT A MERRIMAN, a director at $MDB, decided to sell 5,602 shares of the company, which amounted to around $1,796,169. This transaction represents nearly 0.5% of Merriman’s total holdings of this particular stock class. Following this sale, Merriman maintains ownership of 1,086,068 shares of $MDB stocks.

Over the past 6 months, $MDB insiders have actively traded the company’s stock a total of 47 times. Interestingly, all 47 of these transactions involved insider sales, with no purchases being made within this timeframe. These operations have included various key figures within the company, such as DEV ITTYCHERIA (President & CEO) and CHARLES M JR HAZARD, who have conducted multiple sales of $MDB stocks. For example, Ittycheria has engaged in 21 sales, totaling 97,254 shares for an estimated $23,835,912, while Hazard has executed four sales, involving 9,003 shares for an approximate value of $2,710,890.

In terms of hedge fund activity related to $MDB, there has been significant movement by institutional investors. In the recent quarter, 393 institutional investors have increased their holdings of $MDB stock, while 426 have decreased their positions. Notable changes include INFINITUM ASSET MANAGEMENT, LLC eliminating 10,464,000 shares (representing a reduction of 99.4%) from their portfolio during Q2 2025, amounting to $2,197,335,360. On the other hand, AQR CAPITAL MANAGEMENT LLC added 1,069,969 shares (a positive increase of 2567.2%) to their portfolio in Q2 2025.

Moreover, analysts on Wall Street have been actively issuing reports and ratings on $MDB. Among the latest ratings provided, 21 firms presented buy recommendations for the stock, with no firms issuing sell ratings. For example, Canaccord Genuity, Needham, and Truist Securities have all offered buy ratings for $MDB in recent days. Price targets have also been set by various analysts, with a median target of $357.5 for $MDB. Analysts like Kingsley Crane, Mike Cikos, and Patrick Walravens have set target prices ranging from $320.0 to $375.0 for the stock.

In conclusion, the recent insider sales, hedge fund activities, analyst ratings, and price targets all contribute to a comprehensive overview of $MDB’s current standing in the market. It is essential to monitor these trends for insights into the company’s performance and potential future developments.